Belladonna Alkaloids With Phenobartbital Tablet while Breastfeeding

Is using Belladonna Alkaloids With Phenobartbital Tablet unsafe in breastfeeding? Can there be bad consequences for baby if I use it while breastfeeding?

Atropine sulfate while Breastfeeding

CAS Number: 51-55-8

Either isolated dose or topical medication are safe for breastfed babies. Anti-cholinergic drugs decrease Prolactin and Oxytocin hormone secretion. Long-standing Atropine treatment could affects mother's milk production. American Academy of Pediatrics: Maternal Medication Usually Compatible With Breastfeeding.

Hyoscyamine sulfate while Breastfeeding

CAS Number: 101-31-5

Use minimal and short-term dosage since anti-cholinergic drug may decrease breast milk production. Not commercially available in Spain

Scopolamine hydrobromide while Breastfeeding

CAS Number: 51-34-3

Scopolamine or Hyoscine is a alcaloid which is naturally found in several plants among Solanacea family. With a similar chemical structure of Atropine, it shows anti-muscarinic and anti-cholinergic effects (decrease in saliva, bronchial, sweat and gastric secretion, tachycardia, pupil dilation, anti-spasmodic effect on the intestine and urinary tract) Most frequently used formulations contain buthylbromurate, methybromurate and hydrobromurate. Skin patches contain purified Scopolamine. Used for prevention of motion-sickness of the traveler and treatment of nausea, post-anesthesia vomiting. Also, as anti-spasmodict and treatment of ophthalmologic disorders. At latest update, relevant published data on excretion into breast milk were not found. Due to a low oral bioavailability that minimizes the presence into the infant's plasma from mother's milk ingested, thus, the expert consensus is that the risk of use while breastfeeding is minimal. (American Academy of Pediatrics - 2013 says that is usually compatible with breastfeeding) Since at small dosage Scopolamine poisoning with alarming symptoms may occur (irritability, delirium, redness of skin, mouth dryness, constipation, urine retention), we would recommend a cautious and moderate use with a dose as low as possible with a delay of at least 3 hours for breastfeeding after medication. Avoid use if the infant is younger than 2 months or premature.

Phenobarbital while Breastfeeding

CAS Number: 50-06-6

It is a barbiturate drug. Because it has a sedative effect, it is being displaced by other anti-epilepsy drugs in the treatment of chronic epilepsy. Excretion into the breast milk is quite variable with concentrations that could reach clinically significant levels. A sedative effect in infants from mothers who were treated has been described, as well as Abstinence Syndrome with spasms after sudden weaning, mostly in newborns. Follow-up for alertness and adequate feeding in the infant is recommended. Plasma level monitoring may be required in infants for both cases in which sedation has occurred or a follow-up for a progressive weaning is desired.

Atropine sulfate while Breastfeeding

CAS Number: 51-55-8

No information is available on the use of atropine during breastfeeding. Long-term use of atropine might reduce milk production or milk letdown, but a single systemic or ophthalmic dose is not likely to interfere with breastfeeding. During long-term use, observe for signs of decreased lactation (e.g., insatiety, poor weight gain).

Scopolamine hydrobromide while Breastfeeding

CAS Number: 51-34-3

No information is available on the use of scopolamine during breastfeeding. Use during labor appears to have a detrimental effect on newborn infants' nursing behavior. Long-term use of scopolamine might reduce milk production or milk letdown, but a single systemic or ophthalmic dose is not likely to interfere with breastfeeding. During long-term use, observe for signs of decreased lactation (e.g., insatiety, poor weight gain). To substantially diminish the amount of drug that reaches the breastmilk after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue.

Phenobarbital while Breastfeeding

CAS Number: 50-06-6

Inter- and intrapatient variability in excretion of phenobarbital into breastmilk is extensive. Phenobarbital in breastmilk apparently can decrease withdrawal symptoms in infants who were exposed in utero, but it can also cause drowsiness in some infants, especially when used with other sedating drugs. Monitor the infant for drowsiness, adequate weight gain, and developmental milestones, especially in younger, exclusively breastfed infants and when using combinations of psychotropic drugs. Sometimes breastfeeding might have to be limited or discontinued because of excessive drowsiness and poor weight gain. If there is concern, measurement of the infant's serum phenobarbital concentration might help rule out toxicity.

What should I do if I am breastfeeding mother and I am already exposed to Belladonna Alkaloids With Phenobartbital Tablet?

My health care provider has asked me to use Belladonna Alkaloids With Phenobartbital Tablet, what to do?

If I am using Belladonna Alkaloids With Phenobartbital Tablet, will my baby need extra monitoring?

Who can I talk to if I have questions about usage of Belladonna Alkaloids With Phenobartbital Tablet in breastfeeding?